Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Robert Westwood, Simon R. Green, Judy H. Chiao, Patricia A. Boone, Jorge Cortes, William Plunkett

Research output: Contribution to journalArticle

Abstract

Purpose: Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine. Patients and Methods: To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days for 2 weeks (days 1 through 3 and days 8 through 10) every 3 to 4 weeks, in refractory-relapse acute leukemia and myelodysplastic syndrome (MDS). A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design. Sapacitabine was escalated from 75 to 375 mg twice daily for 7 days (n = 35) and from 375 to 475 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Results: The DLTs with both schedules were gastrointestinal. The MTDs were 375 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The recommended phase II single-agent dose schedules were 325 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Responses were observed in 13 patients (28%); four were complete responses, and nine were marrow complete responses. Conclusion: Sapacitabine is a new, safely administered, oral deoxycytidine analog that has encouraging activity in leukemia and MDS. Phase II studies are ongoing.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number2
DOIs
StatePublished - Jan 10 2010
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Leukemia
Pharmacokinetics
Deoxycytidine
Appointments and Schedules
Maximum Tolerated Dose
Cytarabine
Nucleosides
Bone Marrow
Recurrence
sapacitabine
Clinical Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Ravandi, F., Westwood, R., ... Plunkett, W. (2010). Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. Journal of Clinical Oncology, 28(2), 285-291. https://doi.org/10.1200/JCO.2009.25.0209

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. / Kantarjian, Hagop; Garcia-Manero, Guillermo; O'Brien, Susan; Faderl, Stefan; Ravandi, Farhad; Westwood, Robert; Green, Simon R.; Chiao, Judy H.; Boone, Patricia A.; Cortes, Jorge; Plunkett, William.

In: Journal of Clinical Oncology, Vol. 28, No. 2, 10.01.2010, p. 285-291.

Research output: Contribution to journalArticle

Kantarjian, H, Garcia-Manero, G, O'Brien, S, Faderl, S, Ravandi, F, Westwood, R, Green, SR, Chiao, JH, Boone, PA, Cortes, J & Plunkett, W 2010, 'Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome', Journal of Clinical Oncology, vol. 28, no. 2, pp. 285-291. https://doi.org/10.1200/JCO.2009.25.0209
Kantarjian, Hagop ; Garcia-Manero, Guillermo ; O'Brien, Susan ; Faderl, Stefan ; Ravandi, Farhad ; Westwood, Robert ; Green, Simon R. ; Chiao, Judy H. ; Boone, Patricia A. ; Cortes, Jorge ; Plunkett, William. / Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 2. pp. 285-291.
@article{670482d500e64ad696ad238c34024b72,
title = "Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome",
abstract = "Purpose: Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine. Patients and Methods: To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days for 2 weeks (days 1 through 3 and days 8 through 10) every 3 to 4 weeks, in refractory-relapse acute leukemia and myelodysplastic syndrome (MDS). A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design. Sapacitabine was escalated from 75 to 375 mg twice daily for 7 days (n = 35) and from 375 to 475 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Results: The DLTs with both schedules were gastrointestinal. The MTDs were 375 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The recommended phase II single-agent dose schedules were 325 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Responses were observed in 13 patients (28{\%}); four were complete responses, and nine were marrow complete responses. Conclusion: Sapacitabine is a new, safely administered, oral deoxycytidine analog that has encouraging activity in leukemia and MDS. Phase II studies are ongoing.",
author = "Hagop Kantarjian and Guillermo Garcia-Manero and Susan O'Brien and Stefan Faderl and Farhad Ravandi and Robert Westwood and Green, {Simon R.} and Chiao, {Judy H.} and Boone, {Patricia A.} and Jorge Cortes and William Plunkett",
year = "2010",
month = "1",
day = "10",
doi = "10.1200/JCO.2009.25.0209",
language = "English (US)",
volume = "28",
pages = "285--291",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Westwood, Robert

AU - Green, Simon R.

AU - Chiao, Judy H.

AU - Boone, Patricia A.

AU - Cortes, Jorge

AU - Plunkett, William

PY - 2010/1/10

Y1 - 2010/1/10

N2 - Purpose: Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine. Patients and Methods: To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days for 2 weeks (days 1 through 3 and days 8 through 10) every 3 to 4 weeks, in refractory-relapse acute leukemia and myelodysplastic syndrome (MDS). A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design. Sapacitabine was escalated from 75 to 375 mg twice daily for 7 days (n = 35) and from 375 to 475 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Results: The DLTs with both schedules were gastrointestinal. The MTDs were 375 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The recommended phase II single-agent dose schedules were 325 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Responses were observed in 13 patients (28%); four were complete responses, and nine were marrow complete responses. Conclusion: Sapacitabine is a new, safely administered, oral deoxycytidine analog that has encouraging activity in leukemia and MDS. Phase II studies are ongoing.

AB - Purpose: Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine. Patients and Methods: To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days for 2 weeks (days 1 through 3 and days 8 through 10) every 3 to 4 weeks, in refractory-relapse acute leukemia and myelodysplastic syndrome (MDS). A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design. Sapacitabine was escalated from 75 to 375 mg twice daily for 7 days (n = 35) and from 375 to 475 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Results: The DLTs with both schedules were gastrointestinal. The MTDs were 375 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The recommended phase II single-agent dose schedules were 325 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Responses were observed in 13 patients (28%); four were complete responses, and nine were marrow complete responses. Conclusion: Sapacitabine is a new, safely administered, oral deoxycytidine analog that has encouraging activity in leukemia and MDS. Phase II studies are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=74949124273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949124273&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.0209

DO - 10.1200/JCO.2009.25.0209

M3 - Article

C2 - 19933907

AN - SCOPUS:74949124273

VL - 28

SP - 285

EP - 291

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -